Table 2.
Interest in Disclosure of Particular Test Results and Under Various Scenarios for All Participants in the Preintervention KADRC Sample
| Item | Mean (SD)a | % (No./Total No.)b |
|---|---|---|
| Interest | ||
| In amyloid imaging results | 4.02 (1.14) | 45.5 (95/209) |
| In cerebrospinal fluid protein levels | 4.03 (1.15) | 46.6 (96/206) |
| In APOE genotype | 4.15 (1.10) | 51.9 (109/210) |
| In cognitive test results | 4.23 (0.99) | 49.8 (108/217) |
| Knowing there might be false-negative or false-positive results | 4.08 (1.15) | 48.6 (104/214) |
| If I knew my estimated risk of developing AD dementia | ||
| I could better prepare my family for the future | 4.33 (0.80) | 49.1 (106/216) |
| I would be comfortable disclosing my risk to my employer | 2.32 (1.18) | 4.9 (10/204) |
| I would be comfortable disclosing my risk to my health insurance company | 2.39 (1.25) | 6.9 (15/216) |
| If I learn or suspect I am at high risk of AD dementia | ||
| I would consider that life is no longer worth living | 1.67 (0.87) | <0.01 (1/216) |
Abbreviations: AD, Alzheimer disease; APOE4, apolipoprotein E4; KADRC, Knight Alzheimer Disease Research Center.
a
On a 5-point Likert-type scale, ranging from 1 (not at all interested or strongly disagree) to 5 (extremely interested or strongly agree).
b
Refers to the proportion of respondents reporting the upper response choice (extremely interested or strongly agree).